Innovent Biologics and Daiichi Sankyo Reach Vanflyta Commercialization Agreement in China
2026-08-10 10:53:44
According to CoinMeta, Innovent Biologics Inc ( IVBXF, 1801. HK ) has reached an exclusive agreement with Daiichi Sankyo ( DSKYF, 4568.T ) to obtain the commercialization rights of Vanflyta ( Quizartinib ) in China. Innovent Biologics stated in a declaration that both parties have signed the relevant agreement.
Bullish 0
Bearish 0Share to 
Source：Internet
This content is for market information only and does not constitute investment advice.
Follow HKWDB official accounts to stay updated
Hot Articles
Refresh
Web3: Circle obtains New York trust license, expanding USDC custody business.
07-31 22:04
Tesla reportedly plans to divest its China business to pave the way for integration with SpaceX.
07-31 21:54
web3: Foreign media: RWA perpetual contracts may expand faster than tokenization
07-31 21:24
Web3: Foreign media: Analysts say the real catalyst for XRP is not the Clarity Act.
07-31 20:55
Foreign media: Trump's children's accounts are unlikely to replace comprehensive family financial planning
07-31 20:24